Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

Currently, there is no effective vaccine to halt HIV transmission. However, pre-exposure prophylaxis (PrEP) with the drug combination Truvada can substantially decrease HIV transmission in individuals at risk. Despite its benefits, Truvada-based PrEP is expensive and needs to be taken once-daily, which often leads to inadequate adherence and incomplete protection. These deficits may be overcome by next-generation PrEP regimen, including currently investigated long-acting formulations, or patent-expired drugs. However, poor translatability of animal- and ex vivo/in vitro experiments, and the necessity to conduct long-term (several years) human trials involving considerable sample sizes (N>1000 individuals) are major obstacles to rationalize drug-candidate selection. We developed a prophylaxis modelling tool that mechanistically considers the mode-of-action of all available drugs. We used the tool to screen antivirals for their prophylactic utility and identify lower bound effective concentrations that can guide dose selection in PrEP trials. While in vitro measurable drug potency usually guides PrEP trial design, we found that it may over-predict PrEP potency for all drug classes except reverse transcriptase inhibitors. While most drugs displayed graded concentration-prophylaxis profiles, protease inhibitors tended to switch between none- and complete protection. While several treatment-approved drugs could be ruled out as PrEP candidates based on lack-of-prophylactic efficacy, darunavir, efavirenz, nevirapine, etravirine and rilpivirine could more potently prevent infection than existing PrEP regimen (Truvada). Notably, some drugs from this candidate set are patent-expired and currently neglected for PrEP repurposing. A next step is to further trim this candidate set by ruling out compounds with ominous safety profiles, to assess different administration schemes in silico and to test the remaining candidates in human trials.

[1]  Alan S. Perelson,et al.  Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection , 2010, Journal of Virology.

[2]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[3]  L. Allen.  An introduction to stochastic processes with applications to biology , 2003 .

[4]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[5]  Yan Zhou,et al.  Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 Infection , 2002, Journal of Virology.

[6]  Charles Poole,et al.  Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.

[7]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[8]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[9]  T. Hallett,et al.  Analytic Review of Modeling Studies of ARV Based PrEP Interventions Reveals Strong Influence of Drug-Resistance Assumptions on the Population-Level Effectiveness , 2013, PloS one.

[10]  Kaleab Z. Abebe,et al.  Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. , 2016, The lancet. HIV.

[11]  Yan Zhou,et al.  T Cells + Cd4 Type 1 Decay following Entry into Resting Kinetics of Human Immunodeficiency Virus , 2004 .

[12]  S. Swindells,et al.  Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection , 2012, AIDS.

[13]  Marie-Claude Boily,et al.  Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. , 2009, The Lancet. Infectious diseases.

[14]  Alan S. Perelson,et al.  Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing , 2010, PloS one.

[15]  Persephone Borrow,et al.  The immune response during acute HIV-1 infection: clues for vaccine development , 2009, Nature Reviews Immunology.

[16]  M. von Kleist,et al.  Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses , 2016, Journal of acquired immune deficiency syndromes.

[17]  A. Perelson,et al.  The probability of HIV infection in a new host and its reduction with microbicides. , 2008, Mathematical biosciences.

[18]  Sally Blower,et al.  Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance , 2011, Scientific reports.

[19]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[20]  S. Khoo,et al.  Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. , 2005, The Journal of antimicrobial chemotherapy.

[21]  Daniel Coombs,et al.  Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection , 2013, SIAM J. Appl. Math..

[22]  C. Schütte,et al.  HIV Quasispecies Dynamics during Pro-Active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs , 2011, PloS one.

[23]  V. Miller,et al.  Protein binding in antiretroviral therapies. , 2003, AIDS research and human retroviruses.

[24]  Wilhelm Huisinga,et al.  Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  James Y. Dai,et al.  Tenofovir-based preexposure prophylaxis for HIV infection among African women. , 2015, The New England journal of medicine.

[26]  Alan S. Perelson,et al.  High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men , 2010, PLoS pathogens.

[27]  M. Schöller-Gyüre,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Etravirine , 2009, Clinical pharmacokinetics.

[28]  Alan S. Perelson,et al.  A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.

[29]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[30]  T. Chun,et al.  HIV reservoirs as obstacles and opportunities for an HIV cure , 2015, Nature Immunology.

[31]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[32]  E. L. Potter,et al.  Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design , 2013, Journal of Virology.

[33]  Martin A. Nowak,et al.  Antiretroviral dynamics determines HIV evolution and predicts therapy outcome , 2012, Nature Medicine.

[34]  Wilhelm Huisinga,et al.  Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  M. von Kleist,et al.  Multiscale Systems‐Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV‐1 , 2016, CPT: pharmacometrics & systems pharmacology.

[36]  S. Ratcliffe,et al.  Heterosexual Transmission of Human Immunodeficiency Virus Type 1 Subtype C: Macrophage Tropism, Alternative Coreceptor Use, and the Molecular Anatomy of CCR5 Utilization , 2009, Journal of Virology.

[37]  Alan S. Perelson,et al.  Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions , 2011, PLoS Comput. Biol..

[38]  Kirk A Easley,et al.  Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations , 2014, Journal of clinical pharmacology.

[39]  C. Hendrix,et al.  The Male Genital Tract Is Not a Pharmacological Sanctuary From Efavirenz , 2011, Clinical pharmacology and therapeutics.

[40]  Robert Glaubius,et al.  Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. , 2013, The Journal of infectious diseases.

[41]  Matthias Egger,et al.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.

[42]  J. McCutchan,et al.  Indinavir Population Pharmacokinetics in Plasma and Cerebrospinal Fluid , 2000, Antimicrobial Agents and Chemotherapy.

[43]  A. Perelson,et al.  Dynamics of HIV infection of CD4+ T cells. , 1993, Mathematical biosciences.

[44]  H. Crauwels,et al.  The effect of rilpivirine on the pharmacokinetics of methadone in HIV‐negative volunteers , 2014, Journal of clinical pharmacology.

[45]  Matthew G Law,et al.  Relation between HIV viral load and infectiousness: a model-based analysis , 2008, The Lancet.

[46]  C. Flexner,et al.  Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers , 2011, Antimicrobial Agents and Chemotherapy.

[47]  Pengxing Cao,et al.  On the extinction probability in models of within-host infection: the role of latency and immunity , 2016, Journal of mathematical biology.

[48]  Cynthia A. Derdeyn,et al.  Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1 , 2009, PLoS pathogens.

[49]  N. Shaheen,et al.  Single- and Multiple-Dose Pharmacokinetics of Darunavir Plus Ritonavir and Etravirine in Semen and Rectal Tissue of HIV-Negative Men , 2012, Journal of acquired immune deficiency syndromes.

[50]  M. Boffito,et al.  Pharmacology lessons from chemoprophylaxis studies. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  C. Hendrix.  Exploring Concentration Response in HIV Pre-Exposure Prophylaxis to Optimize Clinical Care and Trial Design , 2013, Cell.

[52]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[53]  M. Desai,et al.  HCV versus HIV drug discovery: Déjà vu all over again? , 2013, Bioorganic & medicinal chemistry letters.

[54]  Wilhelm Huisinga,et al.  Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV , 2010, PLoS Comput. Biol..

[55]  Jinyan Liu,et al.  Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys , 2014, Nature.

[56]  L. Wahl,et al.  Perspectives on the basic reproductive ratio , 2005, Journal of The Royal Society Interface.

[57]  Christof Schütte,et al.  HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection , 2012, PLoS Comput. Biol..

[58]  A. Perelson.  Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[59]  D. E. Smith,et al.  Steady‐state pharmacokinetics of delavirdine in HIV‐positive patients: Effect on erythromycin breath test , 1997, Clinical pharmacology and therapeutics.

[60]  Lin Shen,et al.  Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle , 2008, Proceedings of the National Academy of Sciences.

[61]  M. Schöller-Gyüre,et al.  Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials , 2011, Antimicrobial Agents and Chemotherapy.

[62]  Davey M. Smith,et al.  The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. , 2011, AIDS.

[63]  R. Siliciano,et al.  Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir , 2009, Antiviral therapy.

[64]  J. Baeten,et al.  Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. , 2012, The Journal of infectious diseases.

[65]  R. Royce,et al.  Sexual transmission of HIV. , 1997, The New England journal of medicine.

[66]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[67]  R. Swanstrom,et al.  Bottlenecks in HIV-1 transmission: insights from the study of founder viruses , 2015, Nature Reviews Microbiology.

[68]  S. Khoo,et al.  Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract , 2011, Antiviral therapy.

[69]  R. Haubrich,et al.  Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. , 2008, The Journal of infectious diseases.

[70]  A. Vassall,et al.  The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies , 2013, PLoS medicine.

[71]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[72]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[73]  W. Tan,et al.  Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. , 1998, Mathematical biosciences.

[74]  C. Schütte,et al.  Quantifying the Impact of Nevirapine-Based Prophylaxis Strategies To Prevent Mother-to-Child Transmission of HIV-1: a Combined Pharmacokinetic, Pharmacodynamic, and Viral Dynamic Analysis To Predict Clinical Outcomes , 2011, Antimicrobial Agents and Chemotherapy.

[75]  Sally Blower,et al.  HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis , 2010, Proceedings of the National Academy of Sciences.

[76]  D. Back,et al.  Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[77]  M. von Kleist,et al.  Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[78]  R. Swanstrom,et al.  Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants , 2009, Journal of Virology.

[79]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[80]  R. Siliciano,et al.  Quantitative evaluation of the antiretroviral efficacy of dolutegravir. , 2016, JCI insight.

[81]  I. Frank,et al.  Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305) , 2016, The Journal of infectious diseases.

[82]  J. Beijnen,et al.  Steady‐State Pharmacokinetics of Twice‐Daily Dosing of Saquinavir Plus Ritonavir in HIV‐1‐Infected Individuals , 2001, Journal of Acquired Immune Deficiency Syndromes.

[83]  J. Gallant,et al.  Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. , 2017, The lancet. HIV.

[84]  Jessica Prince,et al.  Selection bias at the heterosexual HIV-1 transmission bottleneck , 2013, Science.

[85]  Max von Kleist,et al.  Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes , 2018, PLoS Comput. Biol..

[86]  S. Pambuccian,et al.  Glycerol monolaurate prevents mucosal SIV transmission , 2009, Nature.

[87]  Ashley T. Haase,et al.  Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.

[88]  M. Hudgens,et al.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. , 2016, The Journal of infectious diseases.

[89]  C. Schütte,et al.  Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection , 2012, PloS one.

[90]  Lin Shen,et al.  A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection , 2012, Nature Medicine.

[91]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[92]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.